219a.T
The company operates in the healthcare diagnostics segment, providing products and services related to medical research and biotechnology.
Business. The company operates in the healthcare diagnostics segment, providing products and services related to medical research and biotechnology.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the healthcare diagnostics segment, providing products and services related to medical research and biotechnology.
The company maintains a strong liquidity position, with cash and equivalents amounting to ¥6.84 billion, significantly exceeding its total liabilities of ¥481 million. The liquidity FPT (free cash flow to total liabilities) is robust, indicating a high capacity to meet short-term obligations. The current ratio of 22.3 further supports this, showing the company has substantial current assets relative to its current liabilities.
Profitability metrics indicate a relatively modest return on equity (ROE) of 2.65% and return on assets (ROA) of 2.48%. These figures are below the typical thresholds for high-growth biotechnology firms, suggesting the company may not be generating returns at a pace that justifies aggressive valuation multiples. The operating margin, calculated as operating income of ¥272.16 million on revenue of ¥3.03 billion, is 8.99%, which is in line with industry norms for diagnostic firms.
The company's revenue is not segmented by geographic region or product line in the provided data, making it difficult to assess geographic or product concentration risk. However, the absence of disclosed geographic diversification could imply a concentration in a single market, which may expose the company to regional economic or regulatory risks.
Looking ahead, the company is projected to maintain a stable revenue trajectory, with no significant growth or contraction expected in the next fiscal year. The operating cash flow of ¥1.08 billion and free cash flow of ¥214.93 million suggest the company is generating sufficient cash to support operations and potentially fund future growth initiatives.
The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company's capital structure is largely equity-funded, with minimal long-term debt, reducing the risk of financial distress. The dilution potential is also low, as the number of shares outstanding has not changed between basic and diluted shares.
Recent events, including filings and transcripts, do not indicate any material changes in the company's operations or strategic direction. The company's financial performance appears stable, with no significant deviations from historical trends. Analysts have provided a mean price target of ¥4,000.00, with a median and high target also at ¥4,000.00, suggesting a consensus on the stock's valuation.
- The company has a strong liquidity position, with cash and equivalents significantly exceeding liabilities.
- Profitability metrics are modest, with ROE and ROA below typical thresholds for high-growth biotechnology firms.
- The company's capital structure is largely equity-funded, reducing the risk of financial distress.
- Analysts have provided a consistent price target of ¥4,000.00, indicating a stable valuation expectation.
- The company is not expected to experience significant revenue growth or contraction in the next fiscal year.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -94,50 |
| Revenue | —no estimate | —no estimate | 451,0M JPY |
| Operating income | —no estimate | —no estimate | —no estimate |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 219A.T Market data — financials · 2026-05-26
- Heartseed Inc Market data — analyst estimates · 2026-05-26